Cardiovascular outcomes with SGLT2 inhibitors in type 2 diabetes – update from AHA conference

SGLT2 inhibitors are effective glucose lowering treatments with favourable effects on body weight and blood pressure. Recent trials and real world studies show that they also reduce adverse cardiovascular events, heart failure and mortality in high risk patients. The results of the largest study, DECLARE that has recruited over 17000 patients with diabetes at high CV risk, that will report at the AHA conference in November will be presented.

Learning outcomes:

  • Key facts summarising effects of SGLT2 inhibitors on glucose control, weight, blood pressure and their adverse effects
  • Review of recent CV outcomes trials with SGLT2i
  • Understanding of real world CV outcome data in context of trials
  • Presentation of new data from the DECLARE study

Wednesday 14th November 2018

15:15 - 15:45

Diabetes Co-Morbidities: Mental Health & Wellbeing & Renal

Cardiology Icon

Speakers

Professor of Medicine & Honorary Consultant Physician Obesity and Endocrinology Research Theme Lead for Metabolism and Nutrition, University of Liverpool

Our site is intended for UK Healthcare Professionals

Are you a UK Healthcare Professional?

We’re sending you to our partner charity’s site. 

DRWF provide information and support for people with diabetes and their friends & families